8.42 -0.84 (-9.07%) | 02-11 18:47 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() ![]() ![]() |
|||
Targets | 6-month : | 15.7 ![]() |
1-year : | 21.51 ![]() |
Resists | First : | 13.44 ![]() |
Second : | 18.42 ![]() |
Pivot price | 8.77 ![]() |
|||
Supports | First : | 5.4 | Second : | 4.49 |
MAs | MA(5) : | 9.63 ![]() |
MA(20) : | 8.6 ![]() |
MA(100) : | 10.34 ![]() |
MA(250) : | 12.1 ![]() |
|
MACD | MACD : | -0.6 ![]() |
Signal : | -0.8 ![]() |
%K %D | K(14,3) : | 62.2 ![]() |
D(3) : | 74.7 ![]() |
RSI | RSI(14): 42.8 ![]() |
|||
52-week | High : | 23.45 | Low : | 5.4 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ATRA ] has closed above bottom band by 40.5%. Bollinger Bands are 27.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 9.17 - 9.23 | 9.23 - 9.27 |
Low: | 8.18 - 8.25 | 8.25 - 8.3 |
Close: | 8.33 - 8.43 | 8.43 - 8.5 |
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Tue, 11 Feb 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA - Longview News-Journal
Tue, 11 Feb 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA - PR Newswire
Fri, 07 Feb 2025
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Fri, 07 Feb 2025
Atara Biotherapeutics (NASDAQ:ATRA) Stock Quotes, Forecast and News Summary - Benzinga
Tue, 04 Feb 2025
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 6 (M) |
Held by Insiders | 4.07e+006 (%) |
Held by Institutions | 22.1 (%) |
Shares Short | 526 (K) |
Shares Short P.Month | 0 (K) |
EPS | -1.6212e+008 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | -290.3 % |
Operating Margin | -62.5 % |
Return on Assets (ttm) | -57.5 % |
Return on Equity (ttm) | 0 % |
Qtrly Rev. Growth | 2 % |
Gross Profit (p.s.) | 1785.4 |
Sales Per Share | 1.2478e+008 |
EBITDA (p.s.) | -2.5192e+008 |
Qtrly Earnings Growth | -25.4 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -142 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | 0 |
Price to Cash Flow | -0.19 |
Dividend | 0 |
Forward Dividend | 636280 |
Dividend Yield | 0% |
Dividend Pay Date | 2024-11-23 |
Ex-Dividend Date | Invalid DateTime. |